Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy
AbstractRetroviral vector gene therapy is a promising approach to treating HIV-1. However, integrated vectors are mutagens with the potential to dysregulate nearby genes and cause severe adverse side effects. Leukemia has already been a documented severe adverse event in gene therapy clinical trials for the treatment of primary immunodeficiencies. These side effects will need to be reduced or avoided if retroviral vectors are to be used clinically for HIV-1 treatment. The addition of chromatin insulators to retroviral vectors is a potential strategy for reducing adverse side effects. Insulators have already been effectively used in retroviral vectors to reduce genotoxicity in pre-clinical studies. Here, we will review how insulators function, genotoxicity in gene therapy clinical trials, the design of insulated retroviral vectors, promising results from insulated retroviral vector studies, and considerations for the development of insulated retroviral treatment vectors for HIV-1 gene therapy. View Full-Text
Share & Cite This Article
Browning, D.L.; Trobridge, G.D. Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy. Biomedicines 2016, 4, 4.
Browning DL, Trobridge GD. Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy. Biomedicines. 2016; 4(1):4.Chicago/Turabian Style
Browning, Diana L.; Trobridge, Grant D. 2016. "Insulators to Improve the Safety of Retroviral Vectors for HIV Gene Therapy." Biomedicines 4, no. 1: 4.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.